Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protection against ischemic brain damage using propentofylline in gerbils.

J DeLeo1, P Schubert, G W Kreutzberg

  • 1Max Planck Institute for Psychiatry, Department of Neuromorphology, Martinsried, Federal Republic of Germany.

Stroke
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An anatomical substrate of credit assignment in reinforcement learning.

bioRxiv : the preprint server for biology·2025
Same author

PTB airway compression complicated by vascular abnormalities and cardiac involvement: A case series demonstrating diagnosis and management.

Pediatric pulmonology·2024
Same author

Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy.

Brachytherapy·2024
Same author

SARS-CoV-2 coinfection in children with severe airway obstruction due to pulmonary tuberculosis.

Pediatric pulmonology·2024
Same author

Diagnosing diffuse lung disease in children in a middle-income country: the role of open lung biopsy.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2017
Same author

Efficiency of riboflavin and ultraviolet light treatment against high levels of biofilm-derived Staphylococcus epidermidis in buffy coat platelet concentrates.

Vox sanguinis·2017

This study investigates whether the drug propentofylline can protect the brain from damage caused by a temporary lack of blood flow. Researchers tested the drug in gerbils by blocking blood flow to the brain and measuring survival, seizures, and nerve cell loss. The findings suggest that propentofylline offers significant protection to brain cells even when given after the injury occurs. This drug appears more effective than other common sedatives in this specific model of brain injury. These results highlight potential therapeutic avenues for managing ischemic brain conditions.

Area of Science:

  • Neurobiology and ischemic brain damage research
  • Pharmacology of xanthine derivatives including propentofylline

Background:

No prior work had resolved whether specific xanthine derivatives could mitigate neurological injury following temporary blood flow restriction. It was already known that ischemic events frequently cause irreversible nerve cell loss in vulnerable brain regions. Prior research has shown that various pharmacological agents attempt to preserve neuronal integrity during these acute crises. That uncertainty drove the need to evaluate novel compounds in controlled animal models. This gap motivated the current investigation into the efficacy of HWA 285. Previous studies often failed to demonstrate consistent neuroprotection when treatments were delayed after the initial event. Researchers sought to clarify if this specific derivative could function effectively within a therapeutic window. The current study addresses these limitations by testing the agent both before and after the induction of ischemia.

Purpose Of The Study:

The study aimed to evaluate the protective capacity of the xanthine derivative HWA 285 against ischemic brain injury. Researchers sought to determine if this compound could mitigate damage when administered before or after the onset of ischemia. The team investigated whether the drug could preserve hippocampal nerve cells following a temporary reduction in blood flow. They also intended to compare the efficacy of this agent against pentobarbital in a controlled setting. The investigation focused on parameters including neuronal survival, seizure frequency, and overall mortality in the subjects. By testing various administration timings, the researchers hoped to define the therapeutic window for effective intervention. This work was motivated by the need to identify compounds that remain active even after the initial injury occurs. The authors aimed to provide clear evidence regarding the potential of this derivative in managing acute neurological trauma.

Keywords:
neuroprotectionhippocampal neuronscerebral blood flowpharmacological intervention

Frequently Asked Questions

The researchers propose that HWA 285 protects hippocampal CA1 neurons by preventing nerve cell death. Unlike pentobarbital, which failed to show benefits when given one hour post-injury, this xanthine derivative maintained neuronal integrity even with delayed administration.

The investigators utilized densitometry to quantify the intensity of Nissl staining. This technique allowed for the precise assessment of neuronal survival within the CA1 hippocampal subfield four days after the brief ten-minute blood flow restriction.

The team performed surgery two days prior to the occlusion to ensure stable conditions. This preparation involved using pentobarbital and chloral hydrate anesthesia to facilitate the bilateral carotid artery clamping required for the transient forebrain ischemia model.

Related Experiment Videos

Main Methods:

Review approach involved a controlled experimental design using eighty-one Mongolian gerbils to assess drug efficacy. The team induced transient forebrain ischemia by blocking both carotid arteries for specific durations. Researchers administered HWA 285 at varying intervals relative to the surgical procedure. They employed densitometry to analyze Nissl staining intensity within the hippocampal CA1 region. This quantitative technique provided a reliable metric for evaluating neuronal survival four days post-injury. The study compared the effects of the xanthine derivative against a pentobarbital control group. Investigators monitored subjects for the development of convulsions and overall survival rates over twelve days. This methodology ensured a rigorous assessment of the drug's protective capabilities under standardized conditions.

Main Results:

The researchers identified 10 mg/kg as the most effective dose for mitigating neurological injury. Subjects treated with HWA 285 exhibited significant preservation of CA1 neurons even when the drug was delivered one hour after the occlusion ended. In contrast, pentobarbital failed to provide detectable neuronal protection when administered at the same delayed interval. All six untreated gerbils subjected to a fifteen-minute occlusion suffered from convulsions and died within two days. Chronic daily treatment with the xanthine derivative successfully prevented seizures in eight out of nine subjects. Seven of these treated animals survived for more than twelve days following the severe ischemic event. These findings indicate a robust protective effect against both cellular damage and mortality. The data suggest that the compound functions through mechanisms distinct from those of standard sedative agents.

Conclusions:

The authors propose that HWA 285 provides meaningful neuroprotection against damage in the hippocampal CA1 region. Synthesis and implications suggest that this compound remains effective even when administered one hour post-occlusion. The researchers indicate that this drug operates through distinct pathways compared to pentobarbital. Their findings demonstrate that chronic administration successfully reduces the incidence of lethal convulsions. The data imply that treated subjects exhibit improved survival rates following prolonged ischemic insults. The team concludes that the observed benefits are dose-dependent within the tested parameters. These results highlight the potential for xanthine derivatives in managing acute neurological trauma. The study confirms that timely intervention with this agent significantly alters the clinical outcome in this model.

The study utilized 81 Mongolian gerbils to evaluate survival, seizure generation, and neuronal loss. This animal model provided a consistent platform for comparing the drug's efficacy against untreated controls and pentobarbital-treated subjects.

The researchers identified 10 mg/kg as the optimal dose through a systematic dose-response analysis. This specific concentration was chosen to maximize neuroprotection while minimizing potential side effects during the experimental trials.

The authors suggest that HWA 285 might offer a viable therapeutic strategy for clinical conditions involving restricted cerebral blood flow. They emphasize that the drug's ability to prevent convulsions and improve survival warrants further investigation into its unique pharmacological properties.